S3V Vascular Technologies Limited Unlisted Shares Share Price
About The Company
S3V Vascular Technologies Limited Unlisted Shares Unlisted Shares
Financials · IPO timeline · Growth projects
S3V Vascular Technologies is a homegrown (Indian) medical technology company based in Mysuru that focuses on making advanced treatment for heart, brain and vascular diseases safer, simpler and more accessible.
Founded in 2011, the company brings together clinicians and engineers to improve patient outcomes while reducing dependence on expensive imported medical devices.
S3V Vascular Technologies Business Model
S3V’s business model is built around B2B partnerships with hospitals, clinics and healthcare institutions, supplying high-quality devices that reduce dependence on expensive imports while improving patient outcomes.
Its products are also aligned with public healthcare initiatives like Ayushman Bharat, helping expand affordable access to advanced care across India.
1.Drug-eluting coronary stents
.jpg)
2.PTCA balloon dilatation catheters
.jpg)
3.Aspiration and neuro catheters
.jpg)
4.Guidewires and delivery systems
.png)
5.Mechanical thrombectomy systems for stroke care
.jpg)
Alongside domestic growth, the company actively pursues regulatory approvals and global distribution, with the aim of exporting Indian made medical devices worldwide.
News And Business Initiatives OF SV3 Vascular Technologies
According to recent money control news, S3V Vascular Technologies is quietly building one of the most meaningful healthcare manufacturing stories in India. The company is working on India’s first indigenously developed mechanical thrombectomy device, a life-saving tool used to remove clots from brain arteries in acute ischemic stroke cases.
While the procedure itself is widely used globally, access in India has remained limited because most devices are imported and expensive. With financial support from the Technology Development Board (TDB), S3V plans to set up an integrated manufacturing facility at the Medical Devices Park in Oragadam, Tamil Nadu.
From here, the company will manufacture essential neuro intervention products such as microcatheters, guidewires, aspiration catheters and stent retrievers, reducing dependence on imports and improving availability. The initiative has drawn backing from respected investors like A.M. Naik, Madhusudan Kela and Utpal Sheth, signalling growing confidence in India’s medical-device ecosystem. Alongside domestic manufacturing, S3V is pursuing CE and USFDA approvals to gradually enter global markets.
Beyond products, the company plans to work closely with hospitals and provide simulator-based training to doctors, especially in Tier-II cities where access to advanced stroke care remains limited. Integration with public healthcare schemes such as Ayushman Bharat could further improve affordability.
Overall, S3V’s journey reflects a steady, long-term approach, focused not just on scale but on making critical care more accessible and locally sustainable.
Financial Analysis Of S3V Vascular Technologies
Particulars (Rs. Cr) | FY23 | FY24 |
Revenue | 19 | 15.2 |
Expense | 15.3 | 12.6 |
EBITDA | 3.7 | 2.6 |
EBITDA Margin | 19.50% | 17.10% |
Profit Before Tax | 0.7 | -3.1 |
Tax Expense | 0.1 | 0.1 |
Profit After Tax (PAT) | 0.6 | -3.2 |
Net Margin | 3.20% | -21.10% |
Outstanding Shares | 1.3 | 1.9 |
EPS | 0.43 | -2.37 |
While analysing the financials, revenue declined from Rs 19 crore in FY23 to Rs 15.2 crore in FY24, reflecting a strategic shift rather than a collapse in demand. This slowdown happens not due to weakening demand but more due to the company consciously shifting its focus toward building products, strengthening manufacturing capabilities and working on regulatory approvals, rather than chasing short-term sales.
Profitability has also softened during this phase. EBITDA declined from Rs 3.7 crore to Rs 2.6 crore, and margins narrowed from 19.5% to 17.1%. This is largely because fixed costs such as employee expenses, research and development and infrastructure spending continued, even as revenues declined.
By FY24, the company moved from a small profit (Rs 0.6 crore) to a loss of Rs 3.2 crore, resulting in a negative EPS of Rs 2.37, compared to Rs 0.43 the previous year. While this shift into loss may seem concerning at first, while looking at the bigger picture, it is largely focused on higher spending in order to build a future-ready platform, including capacity expansion, manufacturing preparation and regulatory approvals.
In simple terms, the company is spending now to support growth later, rather than facing any fundamental weakness in its business. This is also reflected by the increase in outstanding shares from 1.3 crore to 1.9 crore, which diluted EPS but strengthened the balance sheet with fresh capital. The dilution signals that new investors have entered to support the growth.
Hence, earnings are under pressure in the short term, but if product launches and commercialisation progress as planned, the company has the potential to see a meaningful improvement in revenues and profitability over the coming years.
If commercialisation proceeds as planned, the company’s earnings profile could look very different over the next few years, with better margins and improved profitability.
S3V Vascular Technologies Unlisted Share Price Review
Examining recent price movements, the stock has experienced sharp fluctuations. It moved from the Rs 350 - 365 range to a high of Rs 425, before cooling off and settling near current levels. This kind of movement is common in unlisted stocks due to limited liquidity and bulk deals.
The company has around 1.92 crore shares outstanding in total. Each share has a book value of about Rs 74, which reflects the company’s net worth as per its balance sheet. Since the market price is much higher than the book value, the stock trades at a price-to-book multiple of around 5 times.
S3V Vascular’s unlisted shares are currently trading around Rs 395 per share. At this price, the company’s total market value comes to roughly Rs 758 crore, which represents how much investors are collectively valuing the business today.
How to buy S3V Vascular Technologies Unlisted Share online?
Are you planning to invest in S3V Vascular Technologies Unlisted Share? At Stockify, we provide thorough research, including complete information such as Key Performance Indicators (KPIs), revenue growth, EBITDA margin reports, EPS growth, etc.
Buying S3V Vascular Technologies Unlisted Shares is easy with us. Look at the information above, figure out your requirements, and our experts will assist you. From assistance in buying to KYC verification & payment and transfer of shares, we will take care of everything. Our experts will help you analyse the boAt unlisted shares' performance by providing updated financial year data. Get expert assistance in buying unlisted shares by connecting with Stockify now!
Check S3V Vascular Technologies Unlisted Share Price Today at Stockify
We update theS3V Vascular Technologies Unlisted Share price every day on our platform. If you are looking forward to buying and selling S3V Vascular Technologies Unlisted Shares, stay tuned to check live unlisted share price updates. We keep a keen eye on market trends and fluctuations in S3V Vascular Technologies Unlisted Share and update stock prices daily.
Check PS3V Vascular Technologies Unlisted Share Today, or subscribe to our daily newsletter for regular updates. S3V Vascular Technologies Unlisted Share price right now is Rs 395. You can buy S3V Vascular Technologies Unlisted Shares in a minute by logging into our portal.
Check out prices of other unlisted shares on Stockify
If you want to strengthen your portfolio, check the prices of other unlisted shares in India. At Stockify, we have an extensive collection of highly profitable pre-IPO shares, ESOPs and unlisted shares of top companies. Besides selling and buying boAt unlisted shares in India, you can pick one from healthcare, technology, manufacturing, etc. Check out the updated boAt unlisted share price, review the list of similar unlisted shares in the market below.
Reliance Retail, Pharmeasy, Chennai Super Kings, Anglo-French Drugs & Industries, Carrier Airconditioning, Maverick Simulation Solutions, PL Capital Market Unlisted Shares, Goodluck Defence Unlisted Shares, Fincare Small Finance Bank Ltd Unlisted Shares, Arohan Financial Services Unlisted Shares, Utkarsh Coreinvest Ltd Unlisted Shares, Fino Paytech Ltd Unlisted Shares, Hero Fincorp Ltd Unlisted Shares, National Stock Exchange Ltd Nse Unlisted Shares, National Commodity Derivatives Exchange Ltd Ncdex Unlisted Shares, Metropolitan Stock Exchange MSEI Unlisted Shares, Capital, Small Finance Bank Ltd Unlisted Shares, and Motilal Oswal Home Finance Ltd Unlisted Shares.
Login To Buy S3V Vascular Technologies Unlisted Shares Today!
Strong
Market Position
Consistent
YoY Growth
Experienced
Management
Key Indicators
A snapshot of S3V Vascular Technologies Limited Unlisted Shares's financial health, valuation multiples and capital efficiency at a glance.
Pricing Trends
Financial Performance
| Indicators | 2024 | 2023 |
|---|---|---|
| Revenue | 15.2 | 19.0 |
| Expense | 12.6 | 15.3 |
| EBITDA | 2.6 | 3.7 |
| Other Cost | 5.6 | 3.0 |
| PBT | -3.1 | 0.7 |
| Tax Expense | 0.1 | 0.1 |
| PAT | -3.2 | 0.6 |
| Other Inc./Exp. | 0.0 | 0.0 |
| Net Income | -3.2 | 0.6 |
| Shares O/S | 1.92 | 1.32 |
| EPS (₹) | -2.37 | 0.43 |
| Rev. Growth % | -20.0% | — |
| EBITDA Mgn % | 17.1% | 19.5% |
| Net Mgn % | -21.1% | 3.2% |
| EPS Growth | -651.2% | — |
Registered Address
Management Team
Download Financial Results
Top Unlisted companies
Frequently Asked Questions
Still have questions?
Our expert team typically responds within 30 minutes during market hours.
S3V Vascular Technologies Limited Unlisted Shares Unlisted Shares
S3V Vascular Technologies is a homegrown (Indian) medical technology company based in Mysuru that focuses on making advanced treatment for heart, brain and vascular diseases safer, simpler and more accessible.
Founded in 2011, the company brings together clinicians and engineers to improve patient outcomes while reducing dependence on expensive imported medical devices.
S3V Vascular Technologies Business Model
S3V’s business model is built around B2B partnerships with hospitals, clinics and healthcare institutions, supplying high-quality devices that reduce dependence on expensive imports while improving patient outcomes.
Its products are also aligned with public healthcare initiatives like Ayushman Bharat, helping expand affordable access to advanced care across India.
1.Drug-eluting coronary stents
2.PTCA balloon dilatation catheters
3.Aspiration and neuro catheters
4.Guidewires and delivery systems
5.Mechanical thrombectomy systems for stroke care
Alongside domestic growth, the company actively pursues regulatory approvals and global distribution, with the aim of exporting Indian made medical devices worldwide.
News And Business Initiatives OF SV3 Vascular Technologies
According to recent money control news, S3V Vascular Technologies is quietly building one of the most meaningful healthcare manufacturing stories in India. The company is working on India’s first indigenously developed mechanical thrombectomy device, a life-saving tool used to remove clots from brain arteries in acute ischemic stroke cases.
While the procedure itself is widely used globally, access in India has remained limited because most devices are imported and expensive. With financial support from the Technology Development Board (TDB), S3V plans to set up an integrated manufacturing facility at the Medical Devices Park in Oragadam, Tamil Nadu.
From here, the company will manufacture essential neuro intervention products such as microcatheters, guidewires, aspiration catheters and stent retrievers, reducing dependence on imports and improving availability. The initiative has drawn backing from respected investors like A.M. Naik, Madhusudan Kela and Utpal Sheth, signalling growing confidence in India’s medical-device ecosystem. Alongside domestic manufacturing, S3V is pursuing CE and USFDA approvals to gradually enter global markets.
Beyond products, the company plans to work closely with hospitals and provide simulator-based training to doctors, especially in Tier-II cities where access to advanced stroke care remains limited. Integration with public healthcare schemes such as Ayushman Bharat could further improve affordability.
Overall, S3V’s journey reflects a steady, long-term approach, focused not just on scale but on making critical care more accessible and locally sustainable.
Financial Analysis Of S3V Vascular Technologies
Particulars (Rs. Cr) | FY23 | FY24 |
Revenue | 19 | 15.2 |
Expense | 15.3 | 12.6 |
EBITDA | 3.7 | 2.6 |
EBITDA Margin | 19.50% | 17.10% |
Profit Before Tax | 0.7 | -3.1 |
Tax Expense | 0.1 | 0.1 |
Profit After Tax (PAT) | 0.6 | -3.2 |
Net Margin | 3.20% | -21.10% |
Outstanding Shares | 1.3 | 1.9 |
EPS | 0.43 | -2.37 |
While analysing the financials, revenue declined from Rs 19 crore in FY23 to Rs 15.2 crore in FY24, reflecting a strategic shift rather than a collapse in demand. This slowdown happens not due to weakening demand but more due to the company consciously shifting its focus toward building products, strengthening manufacturing capabilities and working on regulatory approvals, rather than chasing short-term sales.
Profitability has also softened during this phase. EBITDA declined from Rs 3.7 crore to Rs 2.6 crore, and margins narrowed from 19.5% to 17.1%. This is largely because fixed costs such as employee expenses, research and development and infrastructure spending continued, even as revenues declined.
By FY24, the company moved from a small profit (Rs 0.6 crore) to a loss of Rs 3.2 crore, resulting in a negative EPS of Rs 2.37, compared to Rs 0.43 the previous year. While this shift into loss may seem concerning at first, while looking at the bigger picture, it is largely focused on higher spending in order to build a future-ready platform, including capacity expansion, manufacturing preparation and regulatory approvals.
In simple terms, the company is spending now to support growth later, rather than facing any fundamental weakness in its business. This is also reflected by the increase in outstanding shares from 1.3 crore to 1.9 crore, which diluted EPS but strengthened the balance sheet with fresh capital. The dilution signals that new investors have entered to support the growth.
Hence, earnings are under pressure in the short term, but if product launches and commercialisation progress as planned, the company has the potential to see a meaningful improvement in revenues and profitability over the coming years.
If commercialisation proceeds as planned, the company’s earnings profile could look very different over the next few years, with better margins and improved profitability.
S3V Vascular Technologies Unlisted Share Price Review
Examining recent price movements, the stock has experienced sharp fluctuations. It moved from the Rs 350 - 365 range to a high of Rs 425, before cooling off and settling near current levels. This kind of movement is common in unlisted stocks due to limited liquidity and bulk deals.
The company has around 1.92 crore shares outstanding in total. Each share has a book value of about Rs 74, which reflects the company’s net worth as per its balance sheet. Since the market price is much higher than the book value, the stock trades at a price-to-book multiple of around 5 times.
S3V Vascular’s unlisted shares are currently trading around Rs 395 per share. At this price, the company’s total market value comes to roughly Rs 758 crore, which represents how much investors are collectively valuing the business today.
How to buy S3V Vascular Technologies Unlisted Share online?
Are you planning to invest in S3V Vascular Technologies Unlisted Share? At Stockify, we provide thorough research, including complete information such as Key Performance Indicators (KPIs), revenue growth, EBITDA margin reports, EPS growth, etc.
Buying S3V Vascular Technologies Unlisted Shares is easy with us. Look at the information above, figure out your requirements, and our experts will assist you. From assistance in buying to KYC verification & payment and transfer of shares, we will take care of everything. Our experts will help you analyse the boAt unlisted shares' performance by providing updated financial year data. Get expert assistance in buying unlisted shares by connecting with Stockify now!
Check S3V Vascular Technologies Unlisted Share Price Today at Stockify
We update theS3V Vascular Technologies Unlisted Share price every day on our platform. If you are looking forward to buying and selling S3V Vascular Technologies Unlisted Shares, stay tuned to check live unlisted share price updates. We keep a keen eye on market trends and fluctuations in S3V Vascular Technologies Unlisted Share and update stock prices daily.
Check PS3V Vascular Technologies Unlisted Share Today, or subscribe to our daily newsletter for regular updates. S3V Vascular Technologies Unlisted Share price right now is Rs 395. You can buy S3V Vascular Technologies Unlisted Shares in a minute by logging into our portal.
Check out prices of other unlisted shares on Stockify
If you want to strengthen your portfolio, check the prices of other unlisted shares in India. At Stockify, we have an extensive collection of highly profitable pre-IPO shares, ESOPs and unlisted shares of top companies. Besides selling and buying boAt unlisted shares in India, you can pick one from healthcare, technology, manufacturing, etc. Check out the updated boAt unlisted share price, review the list of similar unlisted shares in the market below.
Reliance Retail, Pharmeasy, Chennai Super Kings, Anglo-French Drugs & Industries, Carrier Airconditioning, Maverick Simulation Solutions, PL Capital Market Unlisted Shares, Goodluck Defence Unlisted Shares, Fincare Small Finance Bank Ltd Unlisted Shares, Arohan Financial Services Unlisted Shares, Utkarsh Coreinvest Ltd Unlisted Shares, Fino Paytech Ltd Unlisted Shares, Hero Fincorp Ltd Unlisted Shares, National Stock Exchange Ltd Nse Unlisted Shares, National Commodity Derivatives Exchange Ltd Ncdex Unlisted Shares, Metropolitan Stock Exchange MSEI Unlisted Shares, Capital, Small Finance Bank Ltd Unlisted Shares, and Motilal Oswal Home Finance Ltd Unlisted Shares.
